Home › Companies › XERIS BIOPHARMA HOLDINGS INC. › 2024-2025

XERIS BIOPHARMA HOLDINGS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and XERIS BIOPHARMA HOLDINGS INC.’s Form 8-K, filed 2025-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
167Asset managers
840Fund votes
2025-06-04Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore XERIS BIOPHARMA HOLDINGS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by XERIS BIOPHARMA HOLDINGS INC.

These tallies are XERIS BIOPHARMA HOLDINGS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

XERIS BIOPHARMA HOLDINGS INC. — official shareholder meeting results, meeting held 2025-06-04
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: BJ Bormann	57,050,196	--	--	21,676,213	32,372,503	Majority: yes
Elect Director: James Brady	76,465,887	--	--	2,260,522	32,372,503	Majority: yes
Elect Director: Garheng Kong	75,938,627	--	--	2,787,782	32,372,503	Majority: yes

Source: XERIS BIOPHARMA HOLDINGS INC., Form 8-K, filed with the SEC on 2025-06-04 — read the filing on EDGAR.

How asset managers voted at the XERIS BIOPHARMA HOLDINGS INC. 2024-2025 meeting

Each item below shows how the 167 asset managers that disclosed a XERIS BIOPHARMA HOLDINGS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of XERIS BIOPHARMA HOLDINGS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

94% fund support · no official result

FOR 94%

The 162 asset managers below cast 94% of the shares they voted on this item FOR (55,079,296 for, 3,368,127 against).

FOR: 55,079,296 (94.2%)AGAINST: 3,368,127 (5.8%)ABSTAIN: 28,134 (0.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers.” at XERIS BIOPHARMA HOLDINGS INC., 2024-2025
Asset manager	For	Against	Vote
BlackRock	10,039,555	0	For
Vanguard	8,330,666	0	For
Fidelity	3,623,781	0	For
State Street	3,472,956	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,410,842	0	For
Goldman Sachs	2,235,869	0	For
Nuveen	2,154,475	0	For
TIAA	2,147,069	0	For
Legal & General Investment Management Ltd	0	1,444,317	Against
Invesco	0	1,346,142	Against
Federated Hermes	1,333,681	0	For
Prudential/PGIM	1,216,617	21,400	For
Northern Trust	1,122,203	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	1,112,308	0	For
Knott David M Jr	1,060,000	0	For
Charles Schwab	847,528	0	For
Two Sigma	817,704	0	For
Point72	790,232	0	For
SEI	677,837	0	For
KENNEDY CAPITAL MANAGEMENT LLC	638,249	0	For
AQR	538,007	0	For
MELLON INVESTMENTS Corp	0	535,864	Against
Voss Capital, LP	528,072	0	For
Renaissance	527,620	0	For
Connor, Clark & Lunn Investment Management Ltd.	493,757	0	For

Showing the 25 largest of 162 asset managers. See all 162 in the interactive database.

2. To elect three Class I directors to our board of directors to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: BJ Bormann

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%WITHHELD 28%

FOR: 57,050,196WITHHELD: 21,676,213

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“Elect Director: BJ Bormann”): 57,050,196 for, 21,676,213 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 156,014,050 outstanding shares: 37% for, 14% withheld (50.5% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (21,758,930 for, 0 against).

FOR 90%10%

FOR: 21,758,930 (89.9%)ABSTAIN: 2,454,121 (10.1%)

Largest asset managers voting on “To elect three Class I directors to our board of directors to serve until the 2028 Annual Meeting of Stockhold” at XERIS BIOPHARMA HOLDINGS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	8,107,572	0	For
BlackRock	5,715,392	0	For
Fidelity	3,313,097	0	For
TIAA	2,147,069	0	For
Federated Hermes	658,116	0	For
Charles Schwab	423,583	0	For
Invesco	0	413,785	Abstain
Equitable	250,392	144,830	For
State Street	539	336,354	Abstain
Goldman Sachs	0	311,938	Abstain
SEI	263,185	0	For
QUANTITATIVE MASTER SERIES LLC	241,971	0	For
Prudential/PGIM	227,600	0	For
Lincoln Financial	0	192,280	Abstain
1290 Funds	0	159,475	Abstain
DRIEHAUS MUTUAL FUNDS	0	144,900	Abstain
Principal Exchange-Traded Funds	0	104,254	Abstain
Global X	82,418	0	For
TIFF INVESTMENT PROGRAM	77,615	0	For
Nationwide	44,408	29,222	For
AIG/SunAmerica	0	71,633	Abstain
Brighthouse	0	67,897	Abstain
Northern Trust	0	65,623	Abstain
RBB FUND, INC.	0	63,709	Abstain
John Hancock	0	50,900	Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

3. To elect three Class I directors to our board of directors to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Garheng Kong

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 75,938,627WITHHELD: 2,787,782

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“Elect Director: Garheng Kong”): 75,938,627 for, 2,787,782 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 156,014,050 outstanding shares: 48.7% for, 2% withheld (50.5% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (24,037,221 for, 0 against).

FOR 99.2%

FOR: 24,037,221 (99.3%)ABSTAIN: 175,830 (0.7%)

Largest asset managers voting on “To elect three Class I directors to our board of directors to serve until the 2028 Annual Meeting of Stockhold” at XERIS BIOPHARMA HOLDINGS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	8,107,572	0	For
BlackRock	5,715,392	0	For
Fidelity	3,313,097	0	For
TIAA	2,147,069	0	For
Federated Hermes	658,116	0	For
Charles Schwab	423,583	0	For
Invesco	413,785	0	For
Equitable	250,392	144,830	For
State Street	336,893	0	For
Goldman Sachs	311,938	0	For
SEI	263,185	0	For
QUANTITATIVE MASTER SERIES LLC	241,971	0	For
Prudential/PGIM	227,600	0	For
Lincoln Financial	192,280	0	For
1290 Funds	159,475	0	For
DRIEHAUS MUTUAL FUNDS	144,900	0	For
Principal Exchange-Traded Funds	104,254	0	For
Global X	82,418	0	For
TIFF INVESTMENT PROGRAM	77,615	0	For
Nationwide	73,630	0	For
AIG/SunAmerica	71,633	0	For
Brighthouse	52,014	15,883	For
Northern Trust	65,623	0	For
RBB FUND, INC.	63,709	0	For
John Hancock	50,900	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. To elect three Class I directors to our board of directors to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: James Brady

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 76,465,887WITHHELD: 2,260,522

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“Elect Director: James Brady”): 76,465,887 for, 2,260,522 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 156,014,050 outstanding shares: 49.0% for, 1% withheld (50.5% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (24,197,168 for, 0 against).

FOR 99.9%

FOR: 24,197,168 (99.9%)ABSTAIN: 15,883 (0.1%)

Largest asset managers voting on “To elect three Class I directors to our board of directors to serve until the 2028 Annual Meeting of Stockhold” at XERIS BIOPHARMA HOLDINGS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	8,107,572	0	For
BlackRock	5,715,392	0	For
Fidelity	3,313,097	0	For
TIAA	2,147,069	0	For
Federated Hermes	658,116	0	For
Charles Schwab	423,583	0	For
Invesco	413,785	0	For
Equitable	395,222	0	For
State Street	336,893	0	For
Goldman Sachs	311,938	0	For
SEI	263,185	0	For
QUANTITATIVE MASTER SERIES LLC	241,971	0	For
Prudential/PGIM	227,600	0	For
Lincoln Financial	192,280	0	For
1290 Funds	159,475	0	For
DRIEHAUS MUTUAL FUNDS	144,900	0	For
Principal Exchange-Traded Funds	104,254	0	For
Global X	82,418	0	For
TIFF INVESTMENT PROGRAM	77,615	0	For
Nationwide	73,630	0	For
AIG/SunAmerica	71,633	0	For
Brighthouse	52,014	15,883	For
Northern Trust	65,623	0	For
RBB FUND, INC.	63,709	0	For
John Hancock	50,900	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

5. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATED

100% fund support · no official result

FOR 99.9%

The 48 asset managers below cast 100% of the shares they voted on this item FOR (24,166,869 for, 0 against).

FOR: 24,166,869 (99.9%)ABSTAIN: 15,883 (0.1%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COM” at XERIS BIOPHARMA HOLDINGS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	8,107,572	0	For
BlackRock	5,715,392	0	For
Fidelity	3,313,097	0	For
TIAA	2,147,069	0	For
Federated Hermes	658,116	0	For
Charles Schwab	423,583	0	For
Invesco	413,785	0	For
Equitable	395,222	0	For
State Street	336,893	0	For
Goldman Sachs	311,938	0	For
SEI	263,185	0	For
QUANTITATIVE MASTER SERIES LLC	241,971	0	For
Prudential/PGIM	227,600	0	For
Lincoln Financial	192,280	0	For
1290 Funds	159,475	0	For
DRIEHAUS MUTUAL FUNDS	144,900	0	For
Principal Exchange-Traded Funds	104,254	0	For
Global X	82,418	0	For
TIFF INVESTMENT PROGRAM	77,615	0	For
Nationwide	73,630	0	For
AIG/SunAmerica	71,633	0	For
Brighthouse	52,014	15,883	For
Northern Trust	65,623	0	For
RBB FUND, INC.	63,709	0	For
John Hancock	50,900	0	For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (454,502 for, 0 against).

FOR: 454,502 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at XERIS BIOPHARMA HOLDINGS INC., 2024-2025
Asset manager	For	Vote
ESSEX INVESTMENT MANAGEMENT CO LLC	346,962	For
JPMorgan	63,591	For
FORUM FUNDS II	30,299	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	13,650	For

Largest XERIS BIOPHARMA HOLDINGS INC. shareholders voting in 2024-2025

Ranked by the number of XERIS BIOPHARMA HOLDINGS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 156,014,050 shares outstanding at the time of that meeting.

Top XERIS BIOPHARMA HOLDINGS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	BlackRock	6.44%
2	Vanguard	5.34%
3	Fidelity	2.32%
4	State Street	2.23%
5	GEODE CAPITAL MANAGEMENT, LLC	2.19%
6	Goldman Sachs	1.43%
7	Nuveen	1.38%
8	TIAA	1.38%
9	Legal & General Investment Management Ltd	0.93%
10	Invesco	0.86%

Reported XERIS BIOPHARMA HOLDINGS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

XERIS BIOPHARMA HOLDINGS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	6.92%	13F
Vanguard Group	5.20%	13F
Morgan Stanley	2.75%	13F
Geode Capital	2.18%	13F
State Street	2.13%	13F
D.E. Shaw	1.96%	13F
Goldman Sachs	1.79%	13F
Millennium Management	1.49%	13F
Renaissance Technologies	1.39%	13F
JPMorgan Chase	1.36%	13F

Percentages above are of 156,014,050 shares outstanding, as reported by XERIS BIOPHARMA HOLDINGS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from XERIS BIOPHARMA HOLDINGS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At XERIS BIOPHARMA HOLDINGS INC.'s shareholder meeting held 2025-06-04, in the 2024-2025 proxy season, 167 asset managers reported how they voted in their SEC Form N-PX filings, covering 840 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. XERIS BIOPHARMA HOLDINGS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding advisory basis, the compensation of our named executive officers. — the reporting funds cast 94% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

XERIS BIOPHARMA HOLDINGS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.